Cargando…

Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany

A high vaccination rate of older and particularly chronically ill people against coronavirus disease-2019 (COVID-19) is likely one of the most important factors in containing the pandemic. When Germany’s vaccination campaign started on December 2020, vaccination prioritization was initially carried...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Manuela A., Wieler, Helmut J., Enders, Peter, Buchholz, Hans-Georg, Plachter, Bodo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402474/
https://www.ncbi.nlm.nih.gov/pubmed/34452036
http://dx.doi.org/10.3390/vaccines9080911
_version_ 1783745798292373504
author Hoffmann, Manuela A.
Wieler, Helmut J.
Enders, Peter
Buchholz, Hans-Georg
Plachter, Bodo
author_facet Hoffmann, Manuela A.
Wieler, Helmut J.
Enders, Peter
Buchholz, Hans-Georg
Plachter, Bodo
author_sort Hoffmann, Manuela A.
collection PubMed
description A high vaccination rate of older and particularly chronically ill people against coronavirus disease-2019 (COVID-19) is likely one of the most important factors in containing the pandemic. When Germany’s vaccination campaign started on December 2020, vaccination prioritization was initially carried out starting with older population groups. Side effect rates in 1065 individuals who had received the first dose of the messenger ribonucleic acid (mRNA) vaccine BNT162b2 Tozinameran from BioNTech/Pfizer three weeks earlier were examined retrospectively. An age- and gender-graded data analysis showed clear age and gender differences with regard to vaccine-related adverse effects. In 77% of all individuals over 80 years of age, no local or systemic side effects were reported after the first vaccination, whereas in the age group up to 80 years, only 37% showed no side effects. In the whole study population, 64% of females and 73% of males reported no adverse effects. The initial vaccination with mRNA vaccine BNT162b2 shows an overall low profile of side effects. Particularly in those over 80 years, an extraordinarily good tolerance with equally good effectiveness is evident. The sex comparison showed that women suffer more often from adverse vaccination reactions. In order to achieve sufficient herd immunity, both age- and gender-dependent vaccination reactions and any difference in the maintenance of immunity should be considered in future vaccination strategies.
format Online
Article
Text
id pubmed-8402474
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84024742021-08-29 Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany Hoffmann, Manuela A. Wieler, Helmut J. Enders, Peter Buchholz, Hans-Georg Plachter, Bodo Vaccines (Basel) Article A high vaccination rate of older and particularly chronically ill people against coronavirus disease-2019 (COVID-19) is likely one of the most important factors in containing the pandemic. When Germany’s vaccination campaign started on December 2020, vaccination prioritization was initially carried out starting with older population groups. Side effect rates in 1065 individuals who had received the first dose of the messenger ribonucleic acid (mRNA) vaccine BNT162b2 Tozinameran from BioNTech/Pfizer three weeks earlier were examined retrospectively. An age- and gender-graded data analysis showed clear age and gender differences with regard to vaccine-related adverse effects. In 77% of all individuals over 80 years of age, no local or systemic side effects were reported after the first vaccination, whereas in the age group up to 80 years, only 37% showed no side effects. In the whole study population, 64% of females and 73% of males reported no adverse effects. The initial vaccination with mRNA vaccine BNT162b2 shows an overall low profile of side effects. Particularly in those over 80 years, an extraordinarily good tolerance with equally good effectiveness is evident. The sex comparison showed that women suffer more often from adverse vaccination reactions. In order to achieve sufficient herd immunity, both age- and gender-dependent vaccination reactions and any difference in the maintenance of immunity should be considered in future vaccination strategies. MDPI 2021-08-16 /pmc/articles/PMC8402474/ /pubmed/34452036 http://dx.doi.org/10.3390/vaccines9080911 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hoffmann, Manuela A.
Wieler, Helmut J.
Enders, Peter
Buchholz, Hans-Georg
Plachter, Bodo
Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany
title Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany
title_full Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany
title_fullStr Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany
title_full_unstemmed Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany
title_short Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany
title_sort age- and sex-graded data evaluation of vaccination reactions after initial injection of the bnt162b2 mrna vaccine in a local vaccination center in germany
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402474/
https://www.ncbi.nlm.nih.gov/pubmed/34452036
http://dx.doi.org/10.3390/vaccines9080911
work_keys_str_mv AT hoffmannmanuelaa ageandsexgradeddataevaluationofvaccinationreactionsafterinitialinjectionofthebnt162b2mrnavaccineinalocalvaccinationcenteringermany
AT wielerhelmutj ageandsexgradeddataevaluationofvaccinationreactionsafterinitialinjectionofthebnt162b2mrnavaccineinalocalvaccinationcenteringermany
AT enderspeter ageandsexgradeddataevaluationofvaccinationreactionsafterinitialinjectionofthebnt162b2mrnavaccineinalocalvaccinationcenteringermany
AT buchholzhansgeorg ageandsexgradeddataevaluationofvaccinationreactionsafterinitialinjectionofthebnt162b2mrnavaccineinalocalvaccinationcenteringermany
AT plachterbodo ageandsexgradeddataevaluationofvaccinationreactionsafterinitialinjectionofthebnt162b2mrnavaccineinalocalvaccinationcenteringermany